Kidney Cancer

>

Latest News

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.
Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

April 6th 2025

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC
Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

March 19th 2025

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.
FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

February 26th 2025

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.
Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

February 26th 2025

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.
Belzutifan Receives European Approval in Localized/Advanced RCC Indications

February 18th 2025

Latest CME Events & Activities

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register Now!

<1
...
2728293031